Condition
Malignant Pleural Mesothelioma
Estimated Enrollment: 30
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment
Study ID Numbers: VS-6063-203
Study First Received: December 2, 2013
Last Updated: February 1, 2017
Estimated Primary Completion Date: January 2017
Primary Outcome Measures:
Assess biomarker responses to VS-6063 in tumor tissue|Evaluate the safety of VS-6063 (defactinib)|Evaluate the pharmacokinetics of VS-6063 (defactinib)|To evaluate the tumor response to VS-6063 (defactinib)
Sponsors and Collaborators:
Verastem, Inc.
Website Link: https://ClinicalTrials.gov/show/NCT02004028
